Insulin-like growth factor 1 receptor inhibits the proliferation of acute myeloid leukaemia cells via NK cell activation.
Acute myeloid leukaemia
Insulin-like growth factor 1 receptor
Natural killer cells
Therapeutic target
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
03
04
2023
accepted:
18
07
2023
medline:
23
8
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
Acute myeloid leukaemia (AML) denotes a heterogeneous category of cancers occurring within the bone marrow that are initiated by the unrestricted proliferation of haematopoietic stem cells. Various factors effectuate the dysregulation of AML cell proliferation; for instance, the upregulation of insulin-like growth factor 1 receptor (IGF1R) within AML cells influences their proliferation. However, there is a current dearth of research assessing the association between IGF1R and prognostic risk as well as its potential as an AML immunotherapeutic. This study aims to elucidate the role of IGF1R in AML progression and evaluate its prognostic value. To this end, RNA-sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA) database was analysed to compare IGF1R expression between AML and normal tissues. Moreover, a Kaplan-Meier survival analysis was performed to determine whether IGF1R expression correlates with patient overall survival (OS). TCGA data revealed upregulated IGF1R expression in the peripheral blood of AML patients compared to that in healthy individuals. Meanwhile, IGF1R expression positively correlates with patient OS. Additionally, elevated IGF1R expression promotes NK cell expansion and enhances its functional activation, thereby inhibiting AML cell proliferation. Collectively, these findings highlight the clinical potential of IGF1R in the effective treatment of AML through the activation of NK cell proliferation and function and suggest that it may represent a potential predictive marker of AML prognosis.
Identifiants
pubmed: 37522970
doi: 10.1007/s00277-023-05378-0
pii: 10.1007/s00277-023-05378-0
doi:
Substances chimiques
Insulin-Like Growth Factor I
67763-96-6
IGF1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2353-2364Subventions
Organisme : Peking Union Medical College Hospital Youth Research Foundation
ID : pumch201912367
Organisme : Fundamental Research Funds for the Central Universities
ID : 3332021008
Organisme : Fundamental Research Funds for the Central Universities
ID : 3332021002
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Darici S, Alkhaldi H, Horne G et al (2020) Targeting PI3K/Akt/mTOR in AML: rationale and clinical evidence. J Clin Med 9:2934. https://doi.org/10.3390/jcm9092934
doi: 10.3390/jcm9092934
pubmed: 32932888
pmcid: 7563273
Burnett AK, Russell NH, Hills RK et al (2015) A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125:3878–3885. https://doi.org/10.1182/blood-2015-01-623447
doi: 10.1182/blood-2015-01-623447
pubmed: 25833957
pmcid: 4505010
Stone RM, Mandrekar SJ, Sanford BL et al (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377:454–464. https://doi.org/10.1056/NEJMoa1614359
doi: 10.1056/NEJMoa1614359
pubmed: 28644114
pmcid: 5754190
Borthakur G, Cortes JE, Estey EE et al (2014) Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia: FLAG-GO in patients with CBF AML. Am J Hematol 89:964–968. https://doi.org/10.1002/ajh.23795
doi: 10.1002/ajh.23795
pubmed: 24990142
pmcid: 4431614
Nazha A, Kantarjian H, Ravandi F et al (2013) Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. Am J Hematol 88:961–966. https://doi.org/10.1002/ajh.23544
doi: 10.1002/ajh.23544
pubmed: 23877926
pmcid: 4110914
Burnett AK, Russell NH, Hills RK et al (2013) Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 Trial. J Clin Oncol 31:3360–3368. https://doi.org/10.1200/JCO.2012.47.4874
doi: 10.1200/JCO.2012.47.4874
pubmed: 23940227
Willemze R, Suciu S, Meloni G et al (2014) High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 32:219–228. https://doi.org/10.1200/JCO.2013.51.8571
doi: 10.1200/JCO.2013.51.8571
pubmed: 24297940
Mayer RJ, Davis RB, Schiffer CA et al (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896–903. https://doi.org/10.1056/NEJM199410063311402
doi: 10.1056/NEJM199410063311402
pubmed: 8078551
Koreth J, Schlenk R, Kopecky KJ et al (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301:2349. https://doi.org/10.1001/jama.2009.813
doi: 10.1001/jama.2009.813
pubmed: 19509382
pmcid: 3163846
Röllig C, Bornhäuser M, Thiede C et al (2011) Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 29:2758–2765. https://doi.org/10.1200/JCO.2010.32.8500
doi: 10.1200/JCO.2010.32.8500
pubmed: 21632498
Almeida AM, Ramos F (2016) Acute myeloid leukemia in the older adults. Leuk Res Rep 6:1–7. https://doi.org/10.1016/j.lrr.2016.06.001
doi: 10.1016/j.lrr.2016.06.001
pubmed: 27408788
pmcid: 4927655
Rashidi A, Weisdorf DJ, Bejanyan N (2018) Treatment of relapsed/refractory acute myeloid leukaemia in adults. Br J Haematol 181:27–37. https://doi.org/10.1111/bjh.15077
doi: 10.1111/bjh.15077
pubmed: 29318584
Reville PK, Kadia TM (2021) Maintenance therapy in AML. Front Oncol 10:619085. https://doi.org/10.3389/fonc.2020.619085
doi: 10.3389/fonc.2020.619085
pubmed: 33604298
pmcid: 7884813
Vivier E, Tomasello E, Baratin M et al (2008) Functions of natural killer cells. Nat Immunol 9:503–510. https://doi.org/10.1038/ni1582
doi: 10.1038/ni1582
pubmed: 18425107
Farag SS, Caligiuri MA (2006) Human natural killer cell development and biology. Blood Rev 20:123–137. https://doi.org/10.1016/j.blre.2005.10.001
doi: 10.1016/j.blre.2005.10.001
pubmed: 16364519
Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND (2019) The emergence of natural killer cells as a major target in cancer immunotherapy. Trends Immunol 40:142–158. https://doi.org/10.1016/j.it.2018.12.003
doi: 10.1016/j.it.2018.12.003
pubmed: 30639050
Cany J, Roeven MWH, Hoogstad-van Evert JS et al (2018) Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice. Blood 131:202–214. https://doi.org/10.1182/blood-2017-06-790204
doi: 10.1182/blood-2017-06-790204
pubmed: 29138222
pmcid: 5757681
Miller JS, Soignier Y, Panoskaltsis-Mortari A et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–3057. https://doi.org/10.1182/blood-2004-07-2974
doi: 10.1182/blood-2004-07-2974
pubmed: 15632206
Shokouhifar A, Anani Sarab G, Yazdanifar M et al (2021) Overcoming the UCB HSCs-derived NK cells dysfunction through harnessing RAS/MAPK, IGF-1R and TGF-β signaling pathways. Cancer Cell Int 21:298. https://doi.org/10.1186/s12935-021-01983-z
doi: 10.1186/s12935-021-01983-z
pubmed: 34098947
pmcid: 8185927
Luo L, Zhang Z, Qiu N et al (2021) Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer. Nat Commun 12:2699. https://doi.org/10.1038/s41467-021-23052-9
doi: 10.1038/s41467-021-23052-9
pubmed: 33976188
pmcid: 8113606
Nakamura M, Miyamoto S, Maeda H et al (2004) Low levels of insulin-like growth factor type 1 receptor expression at cancer cell membrane predict liver metastasis in Dukes’ C human colorectal cancers. Clin Cancer Res 10:8434–8441. https://doi.org/10.1158/1078-0432.CCR-04-0430
doi: 10.1158/1078-0432.CCR-04-0430
pubmed: 15623623
Doepfner KT, Spertini O, Arcaro A (2007) Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 21:1921–1930. https://doi.org/10.1038/sj.leu.2404813
doi: 10.1038/sj.leu.2404813
pubmed: 17581609
Chapuis N, Tamburini J, Cornillet-Lefebvre P et al (2010) Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 95:415–423. https://doi.org/10.3324/haematol.2009.010785
doi: 10.3324/haematol.2009.010785
pubmed: 20007139
Zhang J, Huang F-F, Wu D-S et al (2015) SUMOylation of insulin-like growth factor 1 receptor, promotes proliferation in acute myeloid leukemia. Cancer Lett 357:297–306. https://doi.org/10.1016/j.canlet.2014.11.052
doi: 10.1016/j.canlet.2014.11.052
pubmed: 25448401
Chapuis N, Lacombe C, Tamburini J et al (2010) Insulin receptor A and IGF1R in AML—letter. Cancer Res 70:7010.1. https://doi.org/10.1158/0008-5472.CAN-10-0136
doi: 10.1158/0008-5472.CAN-10-0136
Wahner Hendrickson AE, Haluska P, Schneider PA et al (2009) Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res 69:7635–7643. https://doi.org/10.1158/0008-5472.CAN-09-0511
doi: 10.1158/0008-5472.CAN-09-0511
pubmed: 19789352
Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11:329–341. https://doi.org/10.1038/nrm2882
doi: 10.1038/nrm2882
pubmed: 20379207
Martini M, De Santis MC, Braccini L et al (2014) PI3K/AKT signaling pathway and cancer: an updated review. Ann Med 46:372–383. https://doi.org/10.3109/07853890.2014.912836
doi: 10.3109/07853890.2014.912836
pubmed: 24897931
Nepstad I, Hatfield KJ, Grønningsæter IS, Reikvam H (2020) The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci 21:2907. https://doi.org/10.3390/ijms21082907
doi: 10.3390/ijms21082907
pubmed: 32326335
pmcid: 7215987
Myers JA, Miller JS (2021) Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol 18:85–100. https://doi.org/10.1038/s41571-020-0426-7
doi: 10.1038/s41571-020-0426-7
pubmed: 32934330
Ge J, Chen Z, Wu S et al (2009) Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion 80:148–158. https://doi.org/10.1159/000226089
doi: 10.1159/000226089
pubmed: 19713703
Ochnik AM, Baxter RC (2017) Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer. BMC Cancer 17:820. https://doi.org/10.1186/s12885-017-3809-0
doi: 10.1186/s12885-017-3809-0
pubmed: 29207959
pmcid: 5718000
Maris C, D’Haene N, Trépant A-L et al (2015) IGF-IR: a new prognostic biomarker for human glioblastoma. Br J Cancer 113:729–737. https://doi.org/10.1038/bjc.2015.242
doi: 10.1038/bjc.2015.242
pubmed: 26291053
pmcid: 4559821
Zorea J, Prasad M, Cohen L et al (2018) IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer. Cell Death Dis 9:944. https://doi.org/10.1038/s41419-018-1025-8
doi: 10.1038/s41419-018-1025-8
pubmed: 30237504
pmcid: 6148236
Vago L, Gojo I (2020) Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest 130:1552–1564. https://doi.org/10.1172/JCI129204
doi: 10.1172/JCI129204
pubmed: 32235097
pmcid: 7108895
Ni F, Sun R, Fu B et al (2013) IGF1 promotes the development and cytotoxic activity of human NK cells. Nat Commun 4:1479. https://doi.org/10.1038/ncomms2484
doi: 10.1038/ncomms2484
pubmed: 23403580